



BAY-1436032

Catalog No: tcsc0017982

| Available Sizes |
|-------------------------------------------------------------------------|
| Size: 5mg |
| Size: 10mg |
| Size: 25mg |
| Size: 50mg |
| Size: 100mg |
| Specifications |
| CAS No: 1803274-65-8 |
| Formula: $C_{26}^{H}_{30}^{F}_{3}^{N}_{3}^{O}_{3}$ |
| Pathway: Metabolic Enzyme/Protease |
| Target: Isocitrate Dehydrogenase (IDH) |
| Purity / Grade: >98% |
| Solubility: DMSO: 125 mg/mL (255.35 mM; Need ultrasonic and warming) |
| Observed Molecular Weight: 489.53 |



Product Description

BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.

IC50 & Target: IDH1^[1]

In Vitro: BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor. BAY-1436032 inhibits intracellular (R)-2-hydroxyglutarate (R-2HG) production in mouse hematopoietic cells expressing IDH1R132H or IDH1R132C with IC $_{50}$ s of 60 and 45 nM, respectively. R-2HG levels are not reduced in IDH2R140Q and IDH2R172K expressing mouse hematopoietic cells by BAY-1436032 at concentrations up to 10 μ M. Colony growth is inhibited by 50% at a concentration of 0.1 μ M BAY-1436032, while concentrations up to 100 μ M do not suppress colony growth of patient-derived IDH1 wild-type AML cells. On morphologic evaluation myelomonocytic differentiation of myeloid progenitors is strongly induced by BAY-1436032^[1].

In Vivo: Long-term exposure to once daily oral BAY-1436032 reveals nearly complete suppression of (R)-2-hydroxyglutarate (R-2HG) production with 150 mg/kg BAY1436032. White blood cell counts constantly increase in vehicle-treated mice and, at a lower rate, in animals receiving 45 mg/kg BAY-1436032, while they remain constant in the 150 mg/kg cohort. Hemoglobin levels are slightly lower in the vehicle and 45 mg/kg groups as compare to the 150 mg/kg cohort at day 60, while platelet counts are significantly reduced in vehicle and 45 mg/kg BAY-1436032 treated mice compare to the 150 mg/kg cohort at day 60. All mice receiving 150 mg/kg BAY-1436032 survive with minimal hCD45⁺ cell load in their peripheral blood until the end of observation at day 150 after treatment start (P[1].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!